Author(s):
Anjali M. Wanegaonkar, Manisha Chaudhari, Kisan R Jadhav, Vilasrao J. Kadam
Email(s):
anjaliwanegaonkar@gmail.com
DOI:
10.52711/0974-360X.2024.00546
Address:
Anjali M. Wanegaonkar1*, Manisha Chaudhari2, Kisan R Jadhav1, Vilasrao J. Kadam1
1Department of Pharmaceutics, Bharati Vidyapeeth College of Pharmacy, Sector-8 CBD Belapur, Navi Mumbai - 400614, Maharashtra, India.
2DYPatil Deemed to be University, School of Pharmacy, Nerul, Navi Mumbai.
*Corresponding Author
Published In:
Volume - 17,
Issue - 7,
Year - 2024
ABSTRACT:
In recent years, the pharmaceutical industry has paid a lot of attention to the idea of "Quality by Design" (QbD) as a means of preserving quality. It acts as a link between the pharmaceutical sector and drug regulatory agencies, enabling us to advance in a process of pharmaceutical product development that is systematic, risk-based, thorough, and efficient. To ensure the quality of predetermined products, it mostly entails creating and implementing production forms and processes. A few QbD components are establishing the quality profile of the intended product, developing the product and production processes, determining the critical quality attributes, process parameters, and resource diversity, and controlling the production processes to produce consistent quality through time. The goal of this article's is to discuss the concept behind quality-based drug design. By describing and demonstrating how it is possible to check the creation and quality of pharmaceuticals.
Cite this article:
Anjali M. Wanegaonkar, Manisha Chaudhari, Kisan R Jadhav, Vilasrao J. Kadam. Quality by Design: An Over View in Pharma Industry. Research Journal of Pharmacy and Technology. 2024; 17(7):3492-8. doi: 10.52711/0974-360X.2024.00546
Cite(Electronic):
Anjali M. Wanegaonkar, Manisha Chaudhari, Kisan R Jadhav, Vilasrao J. Kadam. Quality by Design: An Over View in Pharma Industry. Research Journal of Pharmacy and Technology. 2024; 17(7):3492-8. doi: 10.52711/0974-360X.2024.00546 Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-7-79
REFERENCE:
1. Woodcock J. The concept of pharmaceutical quality [Internet]. Available from: https://www.researchgate.net/publication/279577343
2. Lionberger RA, Lee SL, Lee LM, Raw A, Yu LX. Quality by design: Concepts for ANDAs. Vol. 10, AAPS Journal. 2008. 268–76.
3. Jain S, John S. Quality by design (QBD): A comprehensive understanding of implementation and challenges in pharmaceuticals development [Internet]. Available from: https://www.researchgate.net/publication/280019162
4. ICH guideline Q9 (R1) on quality risk management Step 2b [Internet]. Available from: www.ema.europa.eu/contact
5. Rajora A, Chhabra G. Quality by Design Approach: Regulatory Need, Current, and Future Perspective. 2021; 14: 2021. Available from: http://dx.doi.org/10.22159/ajpcr.2021v14i6.33733.
6. Medicines Agency E. Committee for Human Medicinal Products ICH guideline Q10 on pharmaceutical quality system Step 5 Transmission to CHMP Date for coming into effect [Internet]. 2015. Available from: www.ema.europa.eu/contact
7. Gandhi A, Roy C. Quality by Design (QbD) in Pharmaceutical Industry: Tools, Perspectives and Challenges. 4: 11.
8. Yu LX. Pharmaceutical quality by design: Product and process development, understanding, and control. 25, Pharmaceutical Research. 2008.781–91.
9. Mccurdy V. Quality by Design.
10. Alam I, Khanam N, Shaikh JK, Ganguly S. Quality by Design-A Recent Trend in Pharmaceutical Industries. Alam al World J Pharm Res [Internet]. 2016; 5: 608. Available from: www.wjpr.net
11. A review on quality by design. Int J Pharm Chem Anal. 2020; 28; 5(1): 1–6.
12. Sharma N, Singh S, Behl T, Gupta N, Gulia R, Kanojia N. Explicating the applications of quality by design tools in optimization of microparticles and nanotechnology based drug delivery systems. Vol. 12, Biointerface Research in Applied Chemistry. AMG Transcend Association; 2022; 4317–36.
13. Bhosle AA, Professor A. QBD in Pharmaceutical Manufacturing: A Systematic Review of Current STATUS, Challenges and Future Perspectives, Saurabh D. Certif J ,Kalkate al World J Pharm Res [Internet]. 2021; 10. Available from: www.wjpr.net
14. Khan AS, Khan F, Rao N. Quality Risk Management in Pharmaceutical Industries. Int J Res Pharm Chem. 2020; Apr 15; 10(2).
15. Abhinandana P, Abhinandana P, Nadendla R. Application of Quality by Design and its Parameters for Pharmaceutical Products A review of various analytical methods on Atrovastatin View project Implementing of Analytical Quality by Design FOR HIGH Quality Pharmaceutical Products View project Application of Quality by Design and its Parameters for Pharmaceutical Products. Int. J. Pharma. Chem. Res. I [Internet]. 3(3). Available from: www.ijpacr.com
16. Elliott P, Billingham S, Bi J, Zhang H. Quality by design for biopharmaceuticals: a historical review and guide for implementation. Pharm Bioprocess. 2013; 1(1): 105–22.
17. Pharmacia Lettre D, Nagar M, Singh Panwar K, Chopra VS, Bala I, Trivedi P. Scholars Research Library Quality by design: A systematic approach to pharmaceutical development [Internet]. Vol. 2. 2010. Available from: www.scholarsresearchlibrary.com
18. Purohit D, Saini M, Pandey P, Tripathy S, Dureja H. Implementation of Quality by Design: A Review. Appl Clin Res Clin Trials Regul Aff. 2019; Jan 18; 6(2): 99–111.
19. V. Das, B. Bhairav, and R. B. Saudagar. Quality by Design approaches to Analytical Method Development. 2017; 10: September, 3188–3194. doi: 10.5958/0974-360X.2017.00567.4.
20. M. D. Kengar, J. A. Tamboli, and C. S. Magdum. Quality by Design in Pharmaceutics. 2019; 11(3): 235–238. doi: 10.5958/0975-4377.2019.00039.9.
21. M. D. Kengar, J. A. Tamboli, and C. S. Magdum. Quality by Design in Pharmaceutics. 2019; 11(3): 235–238. doi: 10.5958/0975-4377.2019.00039.9.
22. V. Das, B. Bhairav, and R. B. Saudagar. Quality by Design approaches to Analytical Method Development. 2017; 10; September: 3188–3194. doi: 10.5958/0974-360X.2017.00567.4.
23. E. M. Agency et al. Report from the EMA-FDA QbD pilot program. vol. 44, no. March 2011, pp. 3–4, 2017.
24. A. V Stadnichenko, Y. M. Krasnopolskiy, T. G. Yarnykh, and А. А. Kotvitskaya. The Concept ‘Quality by Design’ in development of Liposomal cytostatics. 2020; 13; February: 674–678. doi: 10.5958/0974-360X.2020.00129.8.
25. S. Bhattacharyya, H. Adhikari, and D. Regmi. Review Article A brief review on Qbd approach on liposome and the requirements for regulatory approval. 2019; 12; August: 4057–4065. doi: 10.5958/0974-360X.2019.00699.1.
26. S. Savitha and K. Devi. Journal of Drug Delivery and Therapeutics Quality by Design (QbD): A Review. 2022; 12; 234–239.